Enhancing the Predictive Confidence of Preclinical & Translational Cancer Research
Tumour Models London returns in its 7th year and takes a reinvigorated approach towards closing the translational gap between predictable preclinical validation and successful clinical development.
For the last 6 years the Tumour Models Conference has sat at the interface of innovation in model development and therapeutic application.
It continues to serve as an open and collaborative platform enabling pharmaceutical scientists and model developers to explore recent advances in the range of, and impact of in-vitro and in-vivo systems.
The meeting will once again delve into how these models are successfully being utilized for discovery, safety assessment and to enhance confidence in clinical translation of cancer research.
NEW TOPICS FOR 2018:
Strategies centering on model selection and characterisation to optimize preclinical and translational decision making
Modelling drug response in vitro – reviewing of the utility of 3D and microphysiological systems in drug discovery and efficacy testing
Answering which model systems are truly predictive for the identification, assessment & validation of patient-level responses to immunotherapies
Greater focus on rationally modelling next-generation combination therapies to overcome mechanisms of toxicity and resistance
REGISTER YOUR INTEREST TODAY FOR THE TUMOUR MODELS LONDON 2018 MEETING
Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.